In the United States, rare diseases are defined as conditions affecting fewer than 200,000 individuals at any given time. Worldwide, an estimated 300 million people are affected by rare diseases, also known as ''orphan diseases'' because with few financial incentives for developing new treatments, the pharmaceutical industry did not ''adopt'' them. In his book entitled Orphan, Phillip Reilly paints a picture of several rare diseases and the quest to find treatments for them.
Recent years have witnessed a sea change in attention to rare diseases due to the convergence of regulatory, scientific, and societal forces. In 1983, the US Congress enacted the Orphan Drug Act (ODA), providing a number of incentives for companies to work on rare diseases. In addition, the blockbuster drug model focusing on common, highly profitable conditions such as hypertension or hypercholesterolemia proved to be unsustainable for the pharmaceutical industry. Many companies have instead turned to rare diseases, especially those that are genetic in origin and have a well-characterized biological mechanism. Finally, the technologies necessary to intervene in genetic disorders are starting to mature, enabling a number of therapeutic options. It is amidst this synergistic set of circumstances that Reilly's book arrives, describing the advances for some of these disorders, the heroes (parents, scientists, clinicians, companies) behind these advances, and the work left to be done.
Reilly brings a broad and unique perspective on these disorders to his book. With both MD and JD degrees to his credit and board certification in Internal Medicine and Clinical Genetics, he joined the Eunice Kennedy Shriver Center for Mental Retardation in the mid-1980s. There, he provided primary care for 800 adults in a state-run institution for people with severe neurological conditions. He then joined a venture capital firm in 2008 and has been focusing on starting companies to treat rare genetic disorders. This wide range of experiences allows him to move with relative ease between describing the impact of these disorders on individuals and their families to discussing the societal and economic impacts of decisions surrounding these conditions. His work as a physician, geneticist, and venture capitalist, together with his evident interest in history of medicine, contribute to his narrative of the thrilling advances in the area of rare diseases and how they have touched people's lives.
Reilly observes, ''To build a company with the goal of developing a novel, transformative therapy for an orphan genetic disorder one must understand the disorder and its impact on families at a level that can never be attained simply by reading medical journals.'' Accordingly, Orphan is full of stories about individuals Reilly has gotten to know under various circumstances. The most vivid vignettes are those of families affected with rare diseases such as phenylketonuria (PKU), a disease that has come under control with dietary treatments; dystrophic epidermolysis bullosa, a life-threatening skin condition; and X-linked adrenoleukodystrophy, a neurological disorder presenting with cognitive decline in elementary school years. Since 50% of the people affected by rare diseases are children, many of the vignettes highlight their parents. Parents have made enormous contributions to the advances in rare disease treatment by being advocates, lobbyists, and entrepreneurs-but above all, courageous caregivers willing to enroll their children in phase I or II clinical trials.
Other heroes in the book are physicians and scientists who focus on a rare disorder and make it their career to seek a treatment. One distinguished example among many is Roscoe Brady, a physician scientist and outstanding biochemist at the National Institute of Neurological Disorders and Stroke (NINDS). Brady focused on Gaucher disease, a disorder in which the lipid glucocerebroside accumulates in the body, leading to liver and spleen enlargement. Brady and colleagues discovered that the synthesis of this lipid was normal, but its clearance by a key lysosomal enzyme was impaired in people with Gaucher disease. In 1966, 20 years before the gene encoding this enzyme was cloned, Brady proposed treating Gaucher patients with enzyme replacement, but it was not until 1991 that the success of such an approach was demonstrated in a clinical trial using enzyme extracted from placentas. Since then, a recombinant protein replacement approach has been used effectively to treat a number of diseases of lysosomal enzyme deficiency.
Over the last two decades, similar approaches have been approved for a number of rare diseases, but patients must take these medications regularly for the rest of their lives. Newer approaches using gene therapy are trying to change that, and Reilly discusses the ups and downs of this research in detail. Gene therapy is experiencing a renaissance fueled by advances in viral vector technology and is being tested in many ongoing clinical trials, including for rare diseases such as spinal muscular atrophy, the leading genetic cause of infant mortality. To date, only one gene therapy product (Glybera, a drug to treat a rare lipid disorder) is approved in Europe; none are approved in the US. Nonetheless, there is great promise for viral-mediated gene delivery to turn diseases with high mortality into chronic conditions.
In addition to viral gene delivery, other technologies are likely to expand therapeutic possibilities, reduce side effects, and improve efficacy in rare diseases. Reilly summarizes these advancements, such as exon skipping, RNA interference, induced pluripotent stem cells, and gene editing. According to a 2013 American Biopharmaceutical Research Companies report, more than 450 drugs are in development for rare diseases. While this is undoubtedly significant progress, there are still scientific, regulatory, and economic hurdles to drug development for rare diseases. One major scientific obstacle remains the blood-brain barrier, which is impenetrable to many small molecules and almost all biologicals. Given that many rare genetic diseases affect the nervous system, technologies that can traverse the blood-brain barrier are a high priority. In addition, for many diseases, we still do not know how early treatment must be initiated to be effective, so defining the temporal windows critical for treatment is a major challenge. Moreover, clinical trials may be difficult to design for rare diseases due to small patient populations, variability of expression, and lack of validated endpoints, especially for those affecting the central nervous system. These hurdles can be further complicated by diverse mutations in the same disease gene that sometimes require different treatments, as exemplified by recent treatments developed for cystic fibrosis patients carrying only certain mutations. While we have reason to be enthusiastic about the promise of mechanism-based treatments, we need to be realistic about these challenges so that we can overcome them.
''We are all orphans'' is the provocative title of Reilly's final chapter. Copy-number variants and whole-exome analysis studies have revealed that each one of us carries rare changes in our genome that could affect our health. For many of them, we do not yet know whether there is any clinical significance, but some common diseases will likely be caused by a combination of genetic variants, as we are discovering for autism spectrum disorder. Highly penetrant genetic variations may contribute to some of the more than 7,000 diseases that are considered rare diseases, affecting an estimated 20-30 million Americans. The Precision Medicine Initiative put forth by President Obama may therefore have the largest initial impact on rare diseases.
Reilly acknowledges the societal, ethical, and financial considerations in this era of huge progress in rare disease research and treatment. Increased detection during gestation and the potential necessity of treatment at fetal stages raise major ethical issues. As genetic diagnosis technology improves, there will be increased demand for Masterslevel trained genetic counselors, who are already scarce in our healthcare system. As effective therapies become available, there will be fewer reasons to deny genetic diagnostic tests to patients. Moreover, the high cost of certain approved treatments has already attracted attention. Some of the newer therapies will turn chronic costs into large one-time treatment costs. How will such costs be reimbursed? What will the impact be in the developing world? Currently, it is estimated that a quarter of the beds in pediatric hospitals are occupied by patients with genetic diseases. As a child neurologist investigating some of these rare diseases, I suspect that number is underestimated, not accounting for many undiagnosed genetic disorders.
''This book is about the struggle to save the lives of children who, because of a roll of the genetic dice, are born with any one of the more than several thousand rare genetic disorders.'' In Orphan, Reilly skillfully describes the promise and challenges of treating rare diseases and encourages public discourse about where we can be in the next few decades. The book will likely engage not only those working on or affected by rare diseases, but also students and biomedical scientists broadly. Different readers may be drawn to different aspects of the book: resilience of the individuals and families living with these conditions, progress in basic science and technology, or the due diligence process for a startup company. A combination of our resources, participation from families, hard work from physicians and scientists, and the support of industry and funders will be needed to translate genetic discoveries into treatments that will improve the lives of those touched by rare diseases.
